Active autoimmune di sease. 5. Subjects cannot have an active immunodeficiency disorder, e.g. HIV 6304p Protocol 118 04/06/2016 Subjects must meet all of the listed criteria in order to be eligible for study. While on study, patients will be followed for disease progression by their primary oncologis t according to conventional practice standards. Should patients show evidence of progression, they should receive appropriate treatment for their disease through their primary oncologist. They will be removed from the study if their treatment conflicts w ith the eligibility criteria (e.g., concurrent administration of chemotherapy, immune modulators, steroids). 7.